Search | Clinical Trials Finder

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: OTX-TIC; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Petaluma, California • Torrance, California • Roswell, Georgia + 2 more

Conditions: Glaucoma, Open-angle, Ocular Hypertension
Interventions: Travatan; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Travoprost/brinzolamide; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Artesia, California

Conditions: Glaucoma and Ocular Hypertension
Interventions: ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR; Drug
Lead sponsor: Envisia Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Dothan, Alabama

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 1,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Murfreesboro, Tennessee

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops; Combination Product · Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Elevated Intraocular Pressure (IOP)
Interventions: Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug; Combination Product
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Travoprost; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Call For Details, Nebraska

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost, Placebo Vehicle; Drug · Other
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 10
States / cities: Artesia, California • Colorado Springs, Colorado • Lakeland, Florida + 7 more

Conditions: Glaucoma
Interventions: Travatan® Z, Xalatan®; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, Ocular Hypertension
Interventions: latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 40
States / cities: Bellflower, California • Inglewood, California • San Diego, California + 31 more

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Travoprost 0.004%/timolol 0.5% ophthalmic solution, Travoprost ophthalmic solution, 0.004%, Timolol maleate ophthalmic solution, 0.5%; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Open-Angle
Interventions: Travoprost Intraocular Implant, iStent infinite, Sham procedure; Drug · Device · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Glaucoma
Interventions: Travoprost, Latanoprost; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: Xalatan, Travatan Z; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions: Prostaglandin Analog, Timolol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Open Angle Glaucoma and Ocular Hypertension
Interventions: Ophthalmic Insert; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Glaucoma, Angle-Closure, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Search by objective public record fields.

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

A Long-term Safety Study of Once-daily Travatan

IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Travoprost Intraocular Implant + iStent Infinite

Effects of Anti-Glaucoma Medications on the Ocular Surface

How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma